Clinical trial
Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After…
NCT00122265 · AHS Cancer Control Alberta, Other · Terminated
Key facts
| NCT number | NCT00122265 |
|---|---|
| Title | Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal Radiotherapy (RT) for Prostate Cancer |
| Official title | Exploring Genomic, Proteomic and Dosimetric Determinants of Late Toxicity After Three Dimensional Conformal RT for Prostate Cancer |
| Lead sponsor | AHS Cancer Control Alberta, Other |
| Status | Terminated |
| Study type | Observational |
| Conditions | Prostate Cancer |
| Enrollment | 83 |
| Start date | Apr 1, 2003 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Jul 22, 2005 |
| Last update posted | Feb 26, 2016 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: